Searching On:

Disease:

Gene:

MET, Gene Amplification

View:
Expand Collapse No disease selected  - General Description
Mass General Hospital Cancer Center treats patients with many cancer types. To learn more about the different cancer types that can be treated at the Cancer Center, please visit the Cancer Center website at the following page: http://www.massgeneral.org/cancer/services/
Expand Collapse MET  - General Description The MET gene encodes for a protein known as the hepatocyte growth factor (HGF) receptor and belongs to the family of receptor tyrosine kinases (RTKs). RTKs are the first link in a chain that sends signals from the outside of a cell to the parts inside the cell that control different cellular processes, such as cell division, cell proliferation, cell differentiation and cell migration. The HGF receptor is activated when another protein, HGF growth factor, attaches (binds) to it. The activated HGF receptor then activates other proteins inside the cell, leading to activation of a series of signaling pathways. One of these pathways (RAS/RAF/MEK/ERK) helps cells become able to perform specific tasks. Another pathway (PI3K/AKT/mTOR) helps cells survive. Signaling along these pathways is important for the development of a baby in its very early (embryonic) stage, and for the development of muscles, nerves, blood vessels and kidneys. Defects in the MET gene are a cause of liver cancer (hepatocellular carcinoma), a form of kidney cancer (papillary renal cell carcinoma) and stomach (gastric) cancer. Source: Genetics Home ReferenceMET encodes for the receptor tyrosine kinase hepatocyte growth factor (HGF) receptor. The HGF receptor is activated by HGF growth factor and signals primarily through the MAP kinase cascade (RAS/RAF/MEK/ERK), thereby driving proliferation and cell survival. In adults, MET gene amplification has been associated with hepatocellular carcinoma, papillary renal cell carcinoma and gastric cancer. Source: Genetics Home Reference
CLICK IMAGE FOR MORE INFORMATION
The MET gene encodes for a protein known as the hepatocyte growth factor (HGF) receptor and belongs to the family of receptor tyrosine kinases (RTKs). RTKs are the first link in a chain that sends signals from the outside of a cell to the parts inside the cell that control different cellular processes, such as cell division, cell proliferation, cell differentiation and cell migration. The HGF receptor is activated when another protein, HGF growth factor, attaches (binds) to it. The activated HGF receptor then activates other proteins inside the cell, leading to activation of a series of signaling pathways. One of these pathways (RAS/RAF/MEK/ERK) helps cells become able to perform specific tasks. Another pathway (PI3K/AKT/mTOR) helps cells survive. Signaling along these pathways is important for the development of a baby in its very early (embryonic) stage, and for the development of muscles, nerves, blood vessels and kidneys.

Defects in the MET gene are a cause of liver cancer (hepatocellular carcinoma), a form of kidney cancer (papillary renal cell carcinoma) and stomach (gastric) cancer.

Source: Genetics Home Reference
MET encodes for the receptor tyrosine kinase hepatocyte growth factor (HGF) receptor. The HGF receptor is activated by HGF growth factor and signals primarily through the MAP kinase cascade (RAS/RAF/MEK/ERK), thereby driving proliferation and cell survival. In adults, MET gene amplification has been associated with hepatocellular carcinoma, papillary renal cell carcinoma and gastric cancer.

Source: Genetics Home Reference
Expand Collapse Gene Amplification  in MET
Gene amplification occurs when a region of DNA that contains a gene is duplicated. Amplification of the MET gene has been tightly linked to overexpression of the Met protein in cancer cells.
Gene amplification occurs when a region of DNA that contains a gene is duplicated. Amplification of the MET gene has been tightly linked to overexpression of the Met protein in cancer cells.

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (G) - Gene, (M) - Mutation
Trial Status: Showing all 6 results Per Page:
Protocol # Title Location Status Match
NCT02099058 A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors MGH Open GM
NCT02228811 A Study of DCC-2701 in Participants With Advanced Solid Tumors A Study of DCC-2701 in Participants With Advanced Solid Tumors MGH Open GM
NCT00585195 A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer MGH Open GM
NCT02219711 Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer MGH Open GM
NCT02750215 A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor MGH Open G
NCT02584634 Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) MGH Open G
MGH has many open clinical trials for other cancers not shown on the Targeted Cancer Care website. They can be found on the MassGeneral.org clinical trials search page.

Additional clinical trials may be applicable to your search criteria, but they may not be available at MGH. These clinical trials can typically be found by searching the clinicaltrials.gov website.
Trial Status: Showing all 6 results Per Page:

Share with your Physican

Print information for your Physician.

Print information